Crestor Tablet 10 mg

Country: Jordan

Language: English

Source: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Active ingredient:

Rosuvastatin 10 mg

Available from:

مستودع ادوية شاوي و رشيدات و مسنات - Shawi & Rushedat Drug Store

ATC code:

C10AA07

INN (International Name):

Rosuvastatin 10 mg

Dosage:

10 mg

Units in package:

28

Manufactured by:

اي بي ار فارماسيوتيكلز (امريكا)

Product summary:

11.96 :سعر الجمهور + الضريبة

Patient Information leaflet

1
Crestor 5 mg, 10 mg, 20 mg, 40 mg
rosuvastatin calcium
Film coated tablets
Composition
Each tablet contains 5 mg, 10 mg, 20 mg, or 40 mg of rosuvastatin (as
calcium salt).
Also contains glycerol.
Pharmaceutical form
Film-coated tablet.
Round, yellow coloured (5 mg); round, pink coloured (10 mg and 20 mg);
oval, pink
coloured (40 mg).
Therapeutic indications
Treatment of hypercholesterolaemia
Adults, adolescents and children aged 6 years or older with primary
hypercholesterolaemia (type IIa including heterozygous familial
hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct
to diet when
response to diet and other non-pharmacological treatments (e.g.
exercise, weight
reduction) is inadequate.
Adults, adolescents and children aged 6 years or older with homozygous
familial
hypercholesterolaemia as an adjunct to diet and other lipid lowering
treatments (e.g.
LDL apheresis) or if such treatments are not appropriate.
2
Prevention of Cardiovascular Events
Prevention of major cardiovascular events in patients who are
estimated to have a
high risk for a first cardiovascular event (see Pharmacodynamic
properties), as an
adjunct to correction of other risk factors.
Posology and method of administration
Before treatment initiation the patient should be placed on a standard
cholesterol-
lowering diet that should continue during treatment. The dose should
be
individualised according to the goal of therapy and patient response,
using current
consensus guidelines.
Crestor may be given at any time of day, with or without food.
Treatment of hypercholesterolaemia
The recommended start dose is 5 mg or 10 mg orally once daily in both
statin naïve
or patients switched from another HMG-CoA reductase inhibitor. The
choice of start
dose should take into account the individual patient’s cholesterol
level and future
cardiovascular risk as well as the potential risk for adverse
reactions (see below). A
dose adjustment to the next dose level can be made after 4 weeks, if
necessary (see
Pharmacodynamic properties). In li